Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study

F. R. Ahmann, F. L. Meyskens, S. E. Jones, R. M. Bukowski, J. H. Saiers, D. H. Ryan, J. Costanzi, C. B. Vaughn, C. A. Coltman

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

A phase II trial was conducted to determine the clinical activity of amsacrine (m-AMSA) in patients with heavily pretreated solid tumors, myeloma, and lymphoma at the University of Arizona Cancer Center. Additionally, m-AMSA was evaluated at other Southwest Oncology Group institutions in breast cancer, myeloma, melanoma, and oat cell cancer of the lung. At a dose of 120 mg/m2 given iv every 28 days, 12 partial responses were observed in 221 patients evaluable for response. Some antitumor activity was observed in breast cancer (four responses of 65 patients), non-Hodgkin's lymphoma (three of nine), Hodgkin's disease (two of five), and sarcoma (two of 15). A partial response was also documented in one of two patients with cervical cancer. Among the 135 patients treated at the University of Arizona who were extensively evaluated for toxic effects, only myelosuppression and anemia were seen in a significant number of patients. At this dose and schedule, 29% of patients developed leukopenia of < 3000 cells/mm3, 16% developed a thrombocytopenia of < 100,000 cells/mm3, and 29% had an acute fall in hemoglobin of ≥ 2 g/100 ml. In addition, two patients suffered grand mal seizures which were not clearly drug-related. These results suggest that further study of m-AMSA in lymphoma, sarcoma, and cervical cancer is warranted.

Original languageEnglish (US)
Pages (from-to)697-700
Number of pages4
JournalCancer Treatment Reports
Volume67
Issue number7-8
StatePublished - Nov 9 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Ahmann, F. R., Meyskens, F. L., Jones, S. E., Bukowski, R. M., Saiers, J. H., Ryan, D. H., Costanzi, J., Vaughn, C. B., & Coltman, C. A. (1983). Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study. Cancer Treatment Reports, 67(7-8), 697-700.